Radequinil

Radequinil
Clinical data
ATC code	None;
Identifiers
	IUPAC name 5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one;
CAS Number	219846-31-8;
PubChem CID	22714308;
ChemSpider	11584471;
UNII	2G222T03EY;
CompTox Dashboard (EPA)	DTXSID60944577 ;
Chemical and physical data
Formula	C18H14N4O3
Molar mass	334.335 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cccc(c1)c3nccc2NC(=O)\C(=C/c23)c4nc(C)on4;
	InChI InChI=1S/C18H14N4O3/c1-10-20-17(22-25-10)14-9-13-15(21-18(14)23)6-7-19-16(13)11-4-3-5-12(8-11)24-2/h3-9H,1-2H3,(H,21,23); Key:JQOFKKWHXGQABB-UHFFFAOYSA-N;

Radequinil (INN; AC-3933) is a cognitive enhancer which acts as a partial inverse agonist of the benzodiazepine site of the GABA_A receptor.^[1] It was under development by Dainippon Sumitomo Pharma for the treatment of Alzheimer's disease and made it to phase II clinical trials but development seems to have been halted and it was never marketed.^[1]^[2]

References

1 2 Martocchia A, Falaschi P (2008). "Current Strategies of Therapy in Alzheimer's Disease" (PDF). The Open Neuropsychopharmacology Journal. 1: 19–23. doi:10.2174/1876523800801010019.
↑ Pogacić V, Herrling P (2007). "List of drugs in development for neurodegenerative diseases. Update June 2007". Neuro-Degenerative Diseases. 4 (6): 443–86. doi:10.1159/000107705. PMID 17934328.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.